Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC.
The spot illustrates the struggles many people face when they are trying to lose or control their weight. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help some patients lose weight and keep it off.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7161051-eisai-launches-national-television-campaign-belviq-lorcaserin-hcl-civ
Spending 30 minutes on a treadmill or an elliptical machine a few times each week is not the key to a healthy lifestyle. What’s more important is getting out of your chair, or off the couch, and moving throughout the day – preferably at least once an hour. That’s the logic behind Anytime Fitness’ new “Every Step Counts” campaign – which features reserved parking spots for its members as far away as possible from the gym, in the far corners of the parking lot.
“We care what you do outside the gym every bit as much as when you’re inside one of our facilities,” said Chuck Runyon, CEO and co-founder of Anytime Fitness. “Three hours of rigorous exercise a week is great. But what you do during the other 165 hours each week will really determine whether you’re healthy or not. If you sit in a chair and stare at a computer screen for eight hours a day, without moving every hour or so, then research* shows you’re much more likely to develop a long list of preventable chronic diseases. Sitting too much is the new smoking.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7942951-anytime-fitness-every-step-counts/
Acclaimed comedian and actor Jon Lovitz is talking candidly for the first time about living with severe plaque psoriasis through a national disease awareness campaign called Are You Serious?™. Psoriasis is a chronic autoimmune condition which causes red, scaly plaques on the skin and affects nearly 7.5 million Americans, including Lovitz, who struggled with the condition for 10 years before getting its symptoms under control. Through his distinctive comedic style, Lovitz illustrates several of the everyday challenges faced by people with psoriasis in TV and radio public service announcements (PSAs), an entertaining song parody performed to Maroon 5’s famous hit, “This Love,” and an educational website – SeriousAboutPsoriasis.com.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/seriousaboutpsoriasis/47521/
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
To coincide with the start of a new school year and Attendance Awareness Month, the Ad Council and U.S. Army are releasing a series of new public service advertisements (PSAs) addressing the importance of regular school attendance in middle school in order for students to stay on course to graduate high school. Created pro bono by Publicis Kaplan Thaler, the PSAs illustrate the fact that every absence, in any grade, excused or not, can negatively impact a child’s academic achievement and put their high school graduation at risk. To help parents keep track, two tools are being offered on the campaign website: a “Text2Track” mobile SMS program and a redesigned Attendance Calculator.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63028-ad-council-boost-attendance-absences-add-up
Ridgefield, CT, September 14, 2011 – Landmark public health campaign DRIVE4COPD today announced the unveiling of 24M: The DRIVE4COPD Monument, a visual representation of the impact of chronic obstructive pulmonary disease (COPD) in the United States. Reaching 14 feet at its highest peak and spanning half a football field, this first-of-its-kind monument comprised of 24 large-scale pinwheels to represent the 24 million Americans who may be living with COPD, was designed by internationally renowned artist and sculptor Michael Kalish.
To view Multimedia News Release, go to http://www.multivu.com/players/English/51245-24m-the-drive4copd-monument/
